One-Year Outcomes for Depression and Anxiety in SLE Patients
Abstract
1. Introduction
2. Materials and Methods
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- McGlasson, S.; Wiseman, S.; Wardlaw, J.; Dhaun, N.; Hunt, D.P.J. Neurological Disease in Lupus: Toward a Personalized Medicine Approach. Front. Immunol. 2018, 9, 1146. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Tu, Z.; Zhang, X.; Du, K.; Xie, Z.; Lin, Z. Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: A review. Front. Cell Dev. Biol. 2022, 10, 998328. [Google Scholar] [CrossRef] [PubMed]
- Meszaros, Z.S.; Perl, A.; Faraone, S.V. Psychiatric symptoms in systemic lupus erythematosus: A systematic review. Br. J. Psychol. 2012, 73, 993–1001. [Google Scholar] [CrossRef] [PubMed]
- Fanouriakis, A.; Bertsias, G.; Govoni, M. Editorial: Lupus and the Brain: Advances in Neuropsychiatric Systemic Lupus Erythematosus. Front. Med. 2019, 6, 52. [Google Scholar] [CrossRef] [PubMed]
- Moustafa, A.T.; Moazzami, M.; Engel, L.; Bangert, E.; Hassanein, M.; Marzouk, S.; Kravtsenyuk, M.; Fung, W.; Eder, L.; Su, J.; et al. Prevalence and metric of depression and anxiety in systemic lupus erythematosus: A systematic review and meta-analysis. Semin. Arthritis Rheum. 2020, 50, 84–94. [Google Scholar] [CrossRef]
- Greco, C.M.; Li, T.; Sattar, A.; Kao, A.H.; Danchenko, N.; Edmundowicz, D.; Sutton-Tyrrell, K.; Tracy, R.P.; Kuller, L.H.; Manzi, S. Association between depression and vascular disease in systemic lupus er-ythematosus. J. Rheumatol. 2012, 39, 262–268. [Google Scholar] [CrossRef]
- A Lisitsyna, T.; Vel’Tishchev, D.I.; Seravina, O.F.; Kovalevskaia, O.B.; Marchenko, A.S.; Novikova, D.S.; A Novikov, A.; Aleksandrova, E.N.; Nasonov, E.L. Prevalence of mental disorders in SLE patients: Correlations with the disease activity and comorbid chronic conditions. Ter. Arkh. 2009, 81, 10–16. [Google Scholar]
- Ward, M.M.; Lotstein, D.S.; Bush, T.M.; E Lambert, R.; Van Vollenhoven, R.; Neuwelt, C.M. Psychosocial correlates of morbidity in women with systemic lupus erythematosus. J. Rheumatol. 1999, 26, 2153–2158. [Google Scholar]
- Mok, C.C.; Chan, K.L.; Ho, L.Y. Association of depressive/anxiety symptoms with quality of life and work ability in patients with systemic lupus erythematosus. Clin. Exp. Rheumatol. 2016, 34, 389–395. [Google Scholar]
- Mak, A.; Tang, C.; Ho, R. Serum tumour necrosis factor-alpha is associated with poor health-related quality of life and depressive symptoms in patients with systemic lupus erythematosus. Lupus 2013, 22, 254–261. [Google Scholar] [CrossRef]
- Mok, C.C.; Chan, K.L.; Cheung, E.F.C.; Yip, P.S.F. Suicidal ideation in patients with systemic lupus erythematosus: Incidence and risk factors. Rheumatology 2014, 53, 714–721. [Google Scholar] [CrossRef]
- Xie, L.-F.; Chen, P.-L.; Pan, H.-F.; Tao, J.-H.; Li, X.-P.; Zhang, Y.-J.; Zhai, Y.; Ye, D.-Q. Prevalence and correlates of suicidal ideation in SLE inpatients: Chinese experience. Rheumatol. Int. 2012, 32, 2707–2714. [Google Scholar] [CrossRef]
- Bertsias, G.K.; A Ioannidis, J.P.; Aringer, M.; Bollen, E.; Bombardieri, S.; Bruce, I.N.; Cervera, R.; Dalakas, M.; Doria, A.; Hanly, J.G.; et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: Report of a task force of the EULAR standing committee for clinical affairs. Ann. Rheum. Dis. 2010, 69, 2074–2082. [Google Scholar] [CrossRef]
- Schwartz, N.; Stock, A.D.; Putterman, C. Neuropsychiatric lupus: New mechanistic insights and future treatment directions. Nat. Rev. Rheumatol. 2019, 15, 137–152. [Google Scholar] [CrossRef] [PubMed]
- Duca, L.; Roman, N.; Teodorescu, A.; Ifteni, P. Association between Inflammation and Thrombotic Pathway Link with Pathogenesis of Depression and Anxiety in SLE Patients. Biomolecules 2023, 13, 567. [Google Scholar] [CrossRef]
- Magro-Checa, C.; Zirkzee, E.J.; Huizinga, T.W.; Steup-Beekman, G.M. Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. Drugs 2016, 76, 459–483. [Google Scholar] [CrossRef] [PubMed]
- Papachristos, D.; Oon, S.; Hanly, J.; Nikpour, M. Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review. Semin. Arthritis Rheum. 2021, 51, 49–71. [Google Scholar] [CrossRef] [PubMed]
- Lew, D.; Huang, X.; Kellahan, S.R.; Xian, H.; Eisen, S.; Kim, A.H.J. Anxiety Symptoms Among Patients With Systemic Lupus Erythematosus Persist Over Time and Are Independent of SLE Disease Activity. ACR Open Rheumatol. 2022, 4, 432–440. [Google Scholar] [CrossRef] [PubMed]
- Kellahan, S.R.; Huang, X.; Lew, D.; Xian, H.; Eisen, S.; Kim, A.H.J. Depressed Symptomatology in Systemic Lupus Erythematosus Patients. Arthritis Care Res. 2023, 75, 749–757. [Google Scholar] [CrossRef] [PubMed]
- Antypa, D.; Simos, N.J.; Kavroulakis, E.; Bertsias, G.; Fanouriakis, A.; Sidiropoulos, P.; Boumpas, D.; Papadaki, E. Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: A resting-state f(unctional) MRI study. Lupus Sci. Med. 2021, 8, e000473. [Google Scholar] [CrossRef] [PubMed]
- A Isenberg, D.; Gordon, C. From BILAG to BLIPS—Disease activity assessment in lupus past, present and future. Lupus 2000, 9, 651–654. [Google Scholar] [CrossRef]
- Gladman, D.D.; Ibañez, D.; Urowitz, M.B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 2002, 29, 288–291. [Google Scholar] [PubMed]
- Buyon, J.P.; Petri, M.A.; Kim, M.Y.; Kalunian, K.C.; Grossman, J.; Hahn, B.H.; Merrill, J.T.; Sammaritano, L.; Lockshin, M.; Alarcón, G.S.; et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann. Intern. Med. 2005, 142, 953–962. [Google Scholar] [CrossRef] [PubMed]
- Arora, S.; Isenberg, D.A.; Castrejon, I. Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. Arthritis Care Res. 2020, 72, 27–46. [Google Scholar] [CrossRef] [PubMed]
- Gladman, D.; Ginzler, E.; Goldsmith, C.; Fortin, P.; Liang, M.; Sanchez-Guerrero, J.; Urowitz, M.; Bacon, P.; Bombardieri, S.; Hanly, J.; et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996, 39, 363–369. [Google Scholar] [CrossRef]
- Isenberg, D.; Ramsey-Goldman, R. Assessing patients with lupus: Towards a drug res-ponder index. Rheumatology 1999, 38, 1045–1049. [Google Scholar] [CrossRef] [PubMed]
- Merikangas, K.R. Longitudinal Trajectories of Depression and Anxiety in a Prospective Community StudyThe Zurich Cohort Study. Arch. Gen. Psychiatry 2003, 60, 993–1000. [Google Scholar] [CrossRef] [PubMed]
- Murphy, J.M. Trends in depression and anxiety: Men and women. Acta Psychiatr. Scand. 1986, 73, 113–127. [Google Scholar] [CrossRef] [PubMed]
- Kupcova, I.; Danisovic, L.; Klein, M.; Harsanyi, S. Effects of the COVID-19 pandemic on mental health, anxiety, and depression. BMC Psychol. 2023, 11, 108. [Google Scholar] [CrossRef]
- Zhu, C.; Zhang, T.; Li, Q.; Chen, X.; Wang, K. Depression and Anxiety During the COVID-19 Pandemic: Epidemiology, Mechanism, and Treatment. Neurosci. Bull. 2023, 39, 675–684. [Google Scholar] [CrossRef]
- Mak, A.; Tang, C.S.-K.; Chan, M.-F.; Cheak, A.A.-C.; Ho, R.C.-M. Damage accrual, cumulative glucocorticoid dose and depression predict anxiety in patients with systemic lupus erythematosus. Clin. Rheumatol. 2011, 30, 795–803. [Google Scholar] [CrossRef]
- Skapinakis, P.; Lewis, G.; Mavreas, V. Temporal relations between unexplained fatigue and depression: Longitudinal data from an international study in primary care. Psychosom. Med. 2004, 66, 330–335. [Google Scholar] [CrossRef] [PubMed]
- Chen, H.; Cui, H.; Geng, Y.; Jin, T.; Shi, S.; Li, Y.; Chen, X.; Shen, B. Development of a nomogram prediction model for depression in patients with systemic lupus erythematosus. Front. Psychol. 2022, 13, 951431. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.; Xu, T.; Wu, M. Depression in systemic lupus erythematosus: Modifiable or inheritable? A two-sample mendelian randomization study. Front. Genet. 2022, 13, 988022. [Google Scholar] [CrossRef] [PubMed]
- Jolly, M.; Annapureddy, N.; Arnaud, L.; Devilliers, H. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: Post-hoc analysis of the BLISS-52 Trial. Lupus 2019, 28, 1628–1639. [Google Scholar] [CrossRef] [PubMed]
- Elefante, E.; Tani, C.; Stagnaro, C.; Signorini, V.; Lenzi, B.; Zucchi, D.; Trentin, F.; Carli, L.; Ferro, F.; Mosca, M. Self-reported anxiety and depression in a monocentric cohort of patients with systemic lupus erythematosus: Analysis of prevalence, main determinants, and impact on quality of life. Front. Med. 2022, 9, 859840. [Google Scholar] [CrossRef]
- Lou, Q.-Y.; Li, Z.; Teng, Y.; Xie, Q.-M.; Zhang, M.; Huang, S.-W.; Li, W.-F.; Chen, Y.-F.; Pan, F.-M.; Xu, S.-Q.; et al. Associations of FKBP4 and FKBP5 Gene Polymorphisms with Disease Susceptibility, Glucocorticoid Efficacy, Anxiety, Depression, and Health- Related Quality of Life in Systemic Lupus Erythematosus Patients. Clin. Rheumatol. 2021, 40, 167–179. [Google Scholar] [CrossRef]
- Shinozaki, G.; Jowsey, S.; Amer, H.; Biernacka, J.M.; Colby, C.; Walker, D.; Black, J.; Rundell, J.; Stegall, M.; Mrazek, D.A. Relationship between FKBP5 Polymorphisms and Depression Symptoms among Kidney Transplant Recipients. Depress. Anxiety 2011, 28, 1111–1118. [Google Scholar] [CrossRef] [PubMed]
- Binder, E.B.; Salyakina, D.; Lichtner, P.; Wochnik, G.M.; Ising, M.; Pütz, B.; Papiol, S.; Seaman, S.; Lucae, S.; Kohli, M.A.; et al. Polymorphisms in FKBP5 Are Associated with Increased Recurrence of Depressive Episodes and Rapid Response to Antidepressant Treatment. Nat. Genet. 2004, 36, 1319–1325. [Google Scholar] [CrossRef]
- Roberts, S.; Keers, R.; Breen, G.; Coleman, J.R.I.; Jöhren, P.; Kepa, A.; Lester, K.J.; Margraf, J.; Scheider, S.; Teismann, T.; et al. DNA Methylation of FKBP5 and Response to Exposure-Based Psychological Therapy. Am. J. Med. Genet. Part B Neuropsychiatr. Genet. 2019, 180, 150–158. [Google Scholar] [CrossRef]
- Hirakawa, H.; Akiyoshi, J.; Muronaga, M.; Tanaka, Y.; Ishitobi, Y.; Inoue, A.; Oshita, H.; Aizawa, S.; Masuda, K.; Higuma, H.; et al. FKBP5 Is Associated with Amygdala Volume in the Human Brain and Mood State: A Voxel-Based Morphometry (VBM) Study. Int. J. Psychiatry Clin. Pract. 2016, 20, 106–115. [Google Scholar] [CrossRef] [PubMed]
- Liao, J.; Kang, J.; Li, F.; Li, Q.; Wang, J.; Tang, Q.; Mao, N.; Li, S.; Xie, X. A cross-sectional study on the association of anxiety and depression with the disease activity of systemic lupus erythematosus. BMC Psychiatry 2022, 22, 591. [Google Scholar] [CrossRef] [PubMed]
- Hanly, J.G.; Su, L.; Urowitz, M.B.; Romero-Diaz, J.; Gordon, C.; Bae, S.; Bernatsky, S.; Clarke, A.E.; Wallace, D.J.; Merrill, J.T.; et al. Mood disorders in systemic lupus erythematosus: Results from an international inception cohort study. Arthritis Rheumatol. 2015, 67, 1837–1847. [Google Scholar] [CrossRef] [PubMed]
- Ward, M.M.; Marx, A.S.; Barry, N.N. Psychological distress and changes in the activity of systemic lupus erythematosus. Rheumatology 2002, 41, 184–188. [Google Scholar] [CrossRef] [PubMed]
- Seguí, J.; Ramos-Casals, M.; García-Carrasco, M.; de Flores, T.; Cervera, R.; Valdeés, M.; Font, J.; Ingelmo, M. Psychiatric and psychosocial disorders in patients with systemic lupus erythematosus: A longitudinal study of active and inactive stages of the disease. Lupus 2000, 9, 584–588. [Google Scholar] [CrossRef] [PubMed]
- Davidson, S.K.; Romaniuk, H.; Chondros, P.; Dowrick, C.; Pirkis, J.; Herrman, H.; Fletcher, S.; Gunn, J. Antidepressant treatment for primary care patients with depressive symptoms: Data from the diamond longitudinal cohort study. Aust. N. Z. J. Psychiatry 2020, 54, 367–381. [Google Scholar] [CrossRef]
- Julian, L.J.; Yelin, E.; Yazdany, J.; Panopalis, P.; Trupin, L.; Criswell, L.A.; Katz, P. Depression, medication adherence, and service utilization in systemic lupus erythematosus. Arthritis Care Res. 2009, 61, 240–246. [Google Scholar] [CrossRef]
- Wichniak, A.; Wierzbicka, A.; Walęcka, M.; Jernajczyk, W. Effects of Antidepressants on Sleep. Curr. Psychiatry Rep. 2017, 19, 63. [Google Scholar] [CrossRef]
- Palagini, L.; Tani, C.; Bruno, R.M.; Gemignani, A.; Mauri, M.; Bombardieri, S.; Riemann, D.; Mosca, M. Poor sleep quality in systemic lupus erythematosus: Does it depend on depressive symptoms? Lupus 2014, 23, 1350–1357. [Google Scholar] [CrossRef]
- Chen, L.; Bell, J.S.; Visvanathan, R.; Hilmer, S.N.; Emery, T.; Robson, L.; Hughes, J.M.; Tan, E.C.K. The association between benzodiazepine use and sleep quality in residential aged care facilities: A cross-sectional study. BMC Geriatr. 2016, 16, 196. [Google Scholar] [CrossRef]
- Kanba, S. Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs? J. Psychiatry Neurosci. 2004, 29, 485. [Google Scholar]
- Tang, V.M.; Davies, S.J.C. Anxiolytics: Misuse, Dependence, and Withdrawal Syndromes. In Neuro Psychopharmacotherapy; Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C., Eds.; Springer: Cham, Switzerland, 2022. [Google Scholar] [CrossRef]
Characteristic | Mean ± SD/Percent |
---|---|
Age | 51.48 ± 13.85 [15] |
Active smoking | 15 (23.07%) |
Non-smoking | 50 (76.92%) |
BMI | 26.6963 ± 6.39 |
HBP | 50 (76.92%) |
Dyslipidemia | 52 (80%) |
Diabetes mellitus | 19 (29.23%) |
SLE years | 12.55 ± 8.10 |
SLE treatment | |
Associated corticotherapy | 33/50.76% |
Only corticotherapy | 3/4.62% |
HCQ | 54/84.61% |
Methotrexate | 1/1.54% |
Azathioprine | 1/1.54% |
Micofenolatmofetil + HCQ | 2/3.08% |
Azathioprine + HCQ | 3/4.62% |
Methotrexate + HCQ | 1/1.54% |
SLE major clinical features/organ involvement | |
Mucocutaneous | 53/80% |
Musculoskeletal | 65/100% |
Serositis | 46/70.77% |
Kidney | 18/27.69% |
Cardiac | 17/26.15% |
Neurologic and neuropsychiatric involvement | 35/53.85% |
Hematological | 59/90.77 |
Variable | Association/R2 | B (CI) | p |
---|---|---|---|
HAM A Final | HAM D Initial/0.536 | 1.303 (1–1.61) | <0.0001 |
HAM D Final | HAM A Initial/0.339 | 0.402 (0.26–0.54) | <0.0001 |
HAM D Initial | HAM A Initial/0.664 | 0.538/(0.44–0.63) | <0.0001 |
HAM A Initial | Ham D Initial/0.664 | 1.234 (1.01–1.46) | <0.0001 |
Assessment Scale | Biomarkers | R2 | B | p |
---|---|---|---|---|
HAM A Initial | LA | 0.108 | 6.78 (1.88–11.67) | 0.007 [15] |
C4 | 0.165 | −0.37 (−0.72–0.01) | 0.044 [15] | |
HAM A Final | LA | 0.149 | 9.40 (3.71–14.97) | 0.002 |
Anti RIB P/ | 0.096 | 0.091 (0.02–0.16) | 0.012 | |
Differences of HAM A (Final-Initial) | C4 | 0.156 | 0.41 (0.17–0.65) | 0.001 |
D-dimers | 0.234 | 0.01 (0–0.02) | 0.015 | |
HAM D Initial | Anti RIB P/ | 0.183 | 0.070 (0.33–010) | <0.001 [15] |
PAI | 0.258 | 2.949 (0.60–5.30) | 0.014 [15] | |
Ham D Final | Anti Rib P | 0.336 | 0.098 (0.06–0.13) | <0.001 |
LA | 0.396 | 3.755 (0.74–6.77) | 0.015 | |
Differences of HAM D (Final-Initial) | D-dimers | 0.104 | 0.008 (0.0–0.001) | 0.009 |
Assessment | Biomarkers | R2 | B | p |
---|---|---|---|---|
SLEDAI | Anti Rib P | 0.294 | 0.030 (0.02–0.04) | 0.000 |
ANA | 0.405 | 0.03 (0–0.01) | 0.001 | |
LA | 0.466 | 1.247 (0.30–2.20) | 0.011 | |
P-selectin | 0.518 | −0.029 (−0.05−0.01) | 0.013 | |
BILAG A | ANA | 0.098 | 0.01 (0) | 0.011 |
BILAG B | PAI 1 | 0.192 | 0.497 (0.25–0.74) | 0.000 |
C3 | 0.252 | −0.11 (−0.02–0) | 0.017 | |
ICAM 1 | 0.299 | 0.003 (0–0.01) | 0.027 | |
CRP hs | 0.337 | 0.815 (0.05–1.58) | 0.037 | |
Moderate Activity | PAI | 0.077 | 0.216 (0.04–0.39) | 0.016 |
C3 | 0.127 | −0.007 (−0.1–00) | 0.037 | |
Severe Activity | ANTI SM | 0.158 | 0.030 (0.01–0.005) | 0.001 |
ANA | 0.236 | 0.01 (0) | 0.014 |
Groups and Therapy | Group Therapy (N) | Mean (CI) of Estimates | R2 | p |
---|---|---|---|---|
Depression and NPSLE medication | Anxiolytic (24) | 13.65 (11.46–15.85) | 0.698 | 0.024 |
No therapy (41) | 17.01 (15.42–18.59) | |||
Anxiolytic and antidepressant (20) | 14.13 (11.51–16.74) | 0.734 | 0.003 | |
Antidepressant (7) | 21.18 (17.48–24–87) | |||
Azathioprine+ HCQ (3) | 20.89(15.80–25.98) | 0.745 | 0.024 | |
Methotrexate+ HCQ (1) | 3.87(−4.96–12.69) | |||
Depression and SLE Medication | Azathioprine+ HCQ (3) | 20.89 (15.80–25.98) | 0.075 | 0.030 |
Methotrexate+ HCQ (1) | 3.87 (4.96–12.69) | |||
Anxiety and SLE Medication | None (3) | 30.44 (22.74–38.15) | 0.804 | <0.001 |
Methotrexate+ HCQ (1) | −9.77 (–23.29–3.75) | |||
Azathioprine (1) | 23.20 (9.76–36.64) | 0.019 | ||
Methotrexate + HCQ (1) | −9.77 (–23.29–3.75) | |||
Methotrexate (1) | 45.10 (31.75 –58.45) | 0.017 | ||
Mycophenolate + HCQ (2) | 16.00 (6.37–25.62) | |||
Methotrexate (1) | 45.10 (31.75 −58.45) | 0.023 | ||
HCQ (54) | 21.92 (20.11–23.74) | |||
Plaquenil (54) | 45.10 (31.75 –58.45) | <0.001 | ||
Methotrexate+ HCQ (1) | 16.00 (6.37–25.62) | |||
Azathioprine + HCQ (3) | 21.75 (14.03 –29.47) | 0.03 | ||
Methotrexate + HCQ (1) | −9.77 (–23.29–3.75) |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Duca, L.; Roman, N.A.; Ifteni, P.; Teodorescu, A. One-Year Outcomes for Depression and Anxiety in SLE Patients. Biomedicines 2024, 12, 484. https://doi.org/10.3390/biomedicines12030484
Duca L, Roman NA, Ifteni P, Teodorescu A. One-Year Outcomes for Depression and Anxiety in SLE Patients. Biomedicines. 2024; 12(3):484. https://doi.org/10.3390/biomedicines12030484
Chicago/Turabian StyleDuca, Liliana, Nadinne Alexandra Roman, Petru Ifteni, and Andreea Teodorescu. 2024. "One-Year Outcomes for Depression and Anxiety in SLE Patients" Biomedicines 12, no. 3: 484. https://doi.org/10.3390/biomedicines12030484
APA StyleDuca, L., Roman, N. A., Ifteni, P., & Teodorescu, A. (2024). One-Year Outcomes for Depression and Anxiety in SLE Patients. Biomedicines, 12(3), 484. https://doi.org/10.3390/biomedicines12030484